Overview
Predicting toxicity in elderly patients with head and neck cancer:
validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.
Description
We aim to analyze clinical and biochemical variables to prospectively create and validate an independ-ent predictive score to identify the probability of G3-5 toxicity in HNC elderly patients candidated to a curative treatment with radiation treatment +/- systemic treatment.
Eligibility
Inclusion Criteria:
- Patients aged ≥ 70 years
- Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab)
- Evaluable disease accordingly to RECIST criteria 1.1
- Willing of sign a written informed consent
- Adequate organ function
Exclusion Criteria:
Patient with cancer in other sites than HN < than 2 years except for prostate cancer cT1-2,
Gleason 3+3, NIMBC, initial Non Melanoma Skin Cancer, in situ cervical cancer)
- PS ECOG 3-4
- Patients who received systemic treatments in the past for other primary tumors